Related Experiment Video
Updated: Apr 19, 2026
08:45
Epigenetic Conversion as a Safe and Simple Method to Obtain Insulin-secreting Cells from Adult Skin Fibroblasts
Published on: March 18, 2016
7.3K
Treating type-1 diabetes with an epigenetic drug
Yohko Kitagawa1, Naganari Ohkura2
1Department of Experimental Immunology, World Premier International Immunology Frontier Research Center, Osaka University, Suita, Japan.
Elife
|December 31, 2014
Summary
A novel drug effectively treats type-1 diabetes in mice. It works by reducing inflammation and boosting natural insulin production for better blood sugar control.
Area of Science:
- Immunology
- Endocrinology
- Pharmacology
Background:
- Type-1 diabetes is an autoimmune disease characterized by pancreatic beta-cell destruction.
- Current treatments primarily involve lifelong insulin replacement therapy.
Purpose of the Study:
- To investigate the therapeutic potential of a novel drug in a mouse model of type-1 diabetes.
- To evaluate the drug's effects on pancreatic inflammation and insulin secretion.
Main Methods:
- Administration of the drug to diabetic mice.
- Assessment of inflammatory markers in pancreatic tissue.
- Measurement of insulin levels and glucose tolerance.
Main Results:
- The drug significantly reduced pancreatic inflammation.
- Treated mice showed enhanced insulin production.
- Improved glucose tolerance was observed in the drug-treated group.
Conclusions:
- This single drug demonstrates efficacy in treating type-1 diabetes in mice.
- The drug's mechanism involves both anti-inflammatory effects and direct stimulation of insulin production.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
6.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.5K
01:24Glucagon-like Receptor Agonists
1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
01:26Type I Diabetes II: Pathophysiology
1
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
1
01:12Type I Diabetes I: Introduction
1
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1...
1
01:26Type II Diabetes I: Introduction
2
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
2
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K